Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma
- Wednesday, May 10, 2023, 7:13
- PR Newswire
- Add a comment
Marketing Authorization granted for Tibsovo® as the first and only approved IDH1 targeted therapy in Europe IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma, difficult and hard-to-treat cancer PARIS and BOSTON, May 10, 2023 /PRNewswire/ — Servier, a global…
About the Author
admin has written 21729 stories on this site.